share_log

Thermo Fisher Scientific | 8-K: Thermo Fisher Scientific Reports Second Quarter 2024 Results

Thermo Fisher Scientific | 8-K: Thermo Fisher Scientific Reports Second Quarter 2024 Results

賽默飛世爾 | 8-K:賽默飛世爾科學公佈2024年第二季度業績
美股SEC公告 ·  2024/07/24 18:05

Moomoo AI 已提取核心訊息

Thermo Fisher Scientific reported Q2 2024 revenue of $10.54 billion, down 1% from $10.69 billion in Q2 2023, with core organic revenue growth remaining flat. GAAP diluted EPS increased 15% to $4.04, while adjusted EPS rose 4% to $5.37. The company's adjusted operating margin improved to 22.3% from 22.2% year-over-year.During the quarter, the company launched several innovative products, including the Stellar mass spectrometer and new editions of the Orbitrap Ascend Tribrid mass spectrometer. They also expanded clinical trial supply services with new facilities in the Netherlands and Pennsylvania, while strengthening their presence in Indonesia.The company raised its full-year 2024 guidance, with revenue now expected between $42.4-43.3 billion, up from previous guidance of $42.3-43.3 billion. Adjusted EPS guidance was also increased to $21.29-22.07 from $21.14-22.02. Post-quarter, Thermo Fisher completed the acquisition of Olink, enhancing their protein research capabilities.
Thermo Fisher Scientific reported Q2 2024 revenue of $10.54 billion, down 1% from $10.69 billion in Q2 2023, with core organic revenue growth remaining flat. GAAP diluted EPS increased 15% to $4.04, while adjusted EPS rose 4% to $5.37. The company's adjusted operating margin improved to 22.3% from 22.2% year-over-year.During the quarter, the company launched several innovative products, including the Stellar mass spectrometer and new editions of the Orbitrap Ascend Tribrid mass spectrometer. They also expanded clinical trial supply services with new facilities in the Netherlands and Pennsylvania, while strengthening their presence in Indonesia.The company raised its full-year 2024 guidance, with revenue now expected between $42.4-43.3 billion, up from previous guidance of $42.3-43.3 billion. Adjusted EPS guidance was also increased to $21.29-22.07 from $21.14-22.02. Post-quarter, Thermo Fisher completed the acquisition of Olink, enhancing their protein research capabilities.
賽默飛世爾報告了2024年第二季度營業收入爲105.4億美金,比2023年第二季度的106.9億美金下降1%,核心有機營業收入保持平穩。公認會計原則下的攤薄後每股收益增長15%至4.04美金,而調整後的每股收益上升4%至5.37美金。公司的調整後營業利潤率同比改善至22.3%,高於22.2%。在本季度,公司推出了幾款創新產品,包括恒星質譜儀和新版本的Orbitrap Ascend Tribrid質譜儀。他們還在荷蘭和賓夕法尼亞州擴展了臨牀試驗供應服務,同時加強了在印度尼西亞的業務佈局。該公司將其2024年的全年指引上調,目前預計營業收入在424-433億美金之間,較之前的423-433億美金的指引有所提高。調整後的每股收益指引也從21.14-22.02美金上調至21.29-22.07美金。發帖後,賽默飛完成了對Olink的收購,增強了其蛋白質研究能力。
賽默飛世爾報告了2024年第二季度營業收入爲105.4億美金,比2023年第二季度的106.9億美金下降1%,核心有機營業收入保持平穩。公認會計原則下的攤薄後每股收益增長15%至4.04美金,而調整後的每股收益上升4%至5.37美金。公司的調整後營業利潤率同比改善至22.3%,高於22.2%。在本季度,公司推出了幾款創新產品,包括恒星質譜儀和新版本的Orbitrap Ascend Tribrid質譜儀。他們還在荷蘭和賓夕法尼亞州擴展了臨牀試驗供應服務,同時加強了在印度尼西亞的業務佈局。該公司將其2024年的全年指引上調,目前預計營業收入在424-433億美金之間,較之前的423-433億美金的指引有所提高。調整後的每股收益指引也從21.14-22.02美金上調至21.29-22.07美金。發帖後,賽默飛完成了對Olink的收購,增強了其蛋白質研究能力。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息